
Guray Saydam

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1747139/publications.pdf Version: 2024-02-01



CHIDAV SAVDAM

#	Article	IF	CITATIONS
1	Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study. Lancet Oncology, The, 2017, 18, 88-99.	5.1	205
2	Granulocytic sarcoma: a systematic review. American Journal of Blood Research, 2013, 3, 265-70.	0.6	95
3	The effect of malnutrition on mortality in hospitalized patients with hematologic malignancy. Supportive Care in Cancer, 2020, 28, 1441-1448.	1.0	77
4	Clinical side effects during peripheral blood progenitor cell infusion. Transfusion and Apheresis Science, 2007, 36, 95-101.	0.5	54
5	Ruxolitinib for the treatment of inadequately controlled polycythemia vera without splenomegaly: 80-week follow-up from the RESPONSE-2 trial. Annals of Hematology, 2018, 97, 1591-1600.	0.8	53
6	Cytotoxic and inhibitory effects of 4,4′-dihydroxy chalcone (RVC-588) on proliferation of human leukemic HL-60 cells. Leukemia Research, 2003, 27, 57-64.	0.4	48
7	Involvement of protein phosphatase 2A in interferon-α-2b-induced apoptosis in K562 human chronic myelogenous leukaemia cells. Leukemia Research, 2003, 27, 709-717.	0.4	46
8	The roles of bioactive sphingolipids in resveratrol-induced apoptosis in HL60 acute myeloid leukemia cells. Journal of Cancer Research and Clinical Oncology, 2011, 137, 279-286.	1.2	46
9	Resveratrol Triggers Apoptosis Through Regulating Ceramide Metabolizing Genes in Human K562 Chronic Myeloid Leukemia Cells. Nutrition and Cancer, 2011, 63, 637-644.	0.9	42
10	Radioisotope synovectomy with rhenium186in haemophilic synovitis for elbows, ankles and shoulders. Haemophilia, 2008, 14, 518-523.	1.0	40
11	TARGET: a survey of realâ€world management of chronic myeloid leukaemia across 33 countries. British Journal of Haematology, 2020, 190, 869-876.	1.2	40
12	Dural plasmacytoma mimicking meningioma in a patient with multiple myeloma. Journal of Clinical Neuroscience, 2006, 13, 259-261.	0.8	37
13	Enteral resveratrol supplementation attenuates intestinal epithelial inducible nitric oxide synthase activity and mucosal damage in experimental necrotizing enterocolitis. Journal of Pediatric Surgery, 2007, 42, 1687-1694.	0.8	33
14	Quality of Life and Supportive Care in Multiple Myeloma. Turkish Journal of Haematology, 2013, 30, 234-246.	0.2	31
15	Quercetin-induced apoptosis involves increased hTERT enzyme activity of leukemic cells. Hematology, 2011, 16, 303-307.	0.7	30
16	Arsenic trioxide and methylprednisolone use different signal transduction pathways in leukemic differentiation. Leukemia Research, 2002, 26, 391-398.	0.4	24
17	Repression of STAT3, STAT5A, and STAT5B expressions in chronic myelogenous leukemia cell line K–562 with unmodified or chemically modified siRNAs and induction of apoptosis. Annals of Hematology, 2013, 92, 151-162.	0.8	23
18	Efficacy and safety of ruxolitinib after and versus interferon use in the RESPONSE studies. Annals of Hematology, 2018, 97, 617-627.	0.8	23

#	Article	IF	CITATIONS
19	Augmentation of methylprednisolone-induced differentiation of myeloid leukemia cells by serine/threonine protein phosphatase inhibitors. Leukemia Research, 1999, 23, 507-512.	0.4	22
20	Multidisciplinary clinical management of paroxysmal nocturnal hemoglobinuria. American Journal of Blood Research, 2015, 5, 1-9.	0.6	22
21	Induction of apoptosis by fatty acid ethyl esters in HepG2 cells. Food and Chemical Toxicology, 2005, 43, 139-145.	1.8	21
22	Caffeic acid phenethyl ester triggers apoptosis through induction of loss of mitochondrial membrane potential in CCRF-CEM cells. Journal of Cancer Research and Clinical Oncology, 2011, 137, 41-47.	1.2	21
23	Peripheral blood stem cell mobilization from healthy donors. Transfusion and Apheresis Science, 2015, 53, 13-16.	0.5	20
24	Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience. Annals of Hematology, 2020, 99, 2565-2576.	0.8	19
25	Ruxolitinib versus best available therapy in inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): 5-year follow up of a randomised, phase 3b study. Lancet Haematology,the, 2022, 9, e480-e492.	2.2	18
26	Investigating the Role of JAK/STAT Pathway on Dasatinib-Induced Apoptosis for CML Cell Model K562. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, S161-S166.	0.2	17
27	Antileukemic effect of paclitaxel in combination with metformin in HL-60 cell line. Gene, 2018, 647, 213-220.	1.0	17
28	Cumulative clinical experience from a decade of use: imatinib as first-line treatment of chronic myeloid leukemia. Journal of Blood Medicine, 2012, 3, 139.	0.7	14
29	Turkish Chronic Myeloid Leukemia Study: Retrospective Sectional Analysis of CML Patients. Turkish Journal of Haematology, 2013, 30, 351-358.	0.2	14
30	Ruxolitinib Regulates the Autophagy Machinery in Multiple Myeloma Cells. Anti-Cancer Agents in Medicinal Chemistry, 2020, 20, 2316-2323.	0.9	14
31	Suppression of STAT5A and STAT5B chronic myeloid leukemia cells via siRNA and antisense-oligonucleotide applications with the induction of apoptosis. American Journal of Blood Research, 2013, 3, 58-70.	0.6	14
32	Ruxolitinib induces autophagy in chronic myeloid leukemia cells. Tumor Biology, 2016, 37, 1573-1579.	0.8	13
33	Biochemical and Morphological Characteristics of Selenite-Induced Apoptosis in Human Hepatoma Hep G2 Cells. Biological Trace Element Research, 2004, 99, 027-040.	1.9	12
34	18F-FDG and 18F-NaF PET/CT Findings of a Multiple Myeloma Patient With Thyroid Cartilage Involvement. Clinical Nuclear Medicine, 2015, 40, 873-876.	0.7	12
35	Polycythemia vera: diagnosis, clinical course, and current management. Turkish Journal of Medical Sciences, 2018, 48, 698-710.	0.4	12
36	Brentuximab vedotin consolidation therapy after autologous stemâ€cell transplantation in patients with highâ€risk Hodgkin lymphoma: Multicenter retrospective study. Hematological Oncology, 2021, 39, 498-505.	0.8	12

#	Article	IF	CITATIONS
37	STAT pathway in the regulation of zoledronic acid-induced apoptosis in chronic myeloid leukemia cells. Biomedicine and Pharmacotherapy, 2013, 67, 527-532.	2.5	11
38	Comparative effect of imatinib and ponatinib on autophagy and miRNome in chronic myeloid leukemia. Gene, 2017, 637, 173-180.	1.0	11
39	Effects of Hormone Replacement Therapy on Insulin Resistance and Platelet Function Tests. Medical Principles and Practice, 2009, 18, 43-47.	1.1	10
40	Epstein-Barr virus (EBV) positive diffuse large B cell lymphoma of the elderly—Experience of a single center from Turkey. Pathology Research and Practice, 2013, 209, 471-478.	1.0	10
41	Multicenter Retrospective Analysis of Turkish Patients with Chronic Myeloproliferative Neoplasms. Turkish Journal of Haematology, 2017, 34, 27-33.	0.2	10
42	Protein phosphatase 2A (PP2A) has a potential role in CAPE-induced apoptosis of CCRF-CEM cells via effecting human telomerase reverse transcriptase activity. Hematology, 2007, 12, 519-525.	0.7	9
43	Overnight refrigerator storage of autologous peripheral progenitor stem cells without cryopreservation. Transfusion and Apheresis Science, 2007, 36, 313-319.	0.5	9
44	Methylprednisolone induces apoptosis by interacting with the JAK/STAT pathway in HL-60 and K-562 leukemic cells. Hematology, 2012, 17, 93-99.	0.7	8
45	Bortezomib induces apoptosis by interacting with JAK/STAT pathway in K562 leukemic cells. Tumor Biology, 2014, 35, 7861-7870.	0.8	8
46	PI3K/mTOR dual-inhibition with VS-5584 enhances anti-leukemic efficacy of ponatinib in blasts and Ph-negative LSCs of chronic myeloid leukemia. European Journal of Pharmacology, 2021, 910, 174446.	1.7	8
47	A multi-centric study on the efficacy of eltrombopag in management of refractory chronic immune thrombocytopenia. Turkish Journal of Haematology, 2019, 36, 230-237.	0.2	8
48	Rapid transformation of atypical myeloproliferative disorder with consistent t(8;13) to B-cell acute lymphoblastic leukemia: A case report. Hematology, 2007, 12, 489-492.	0.7	7
49	Eltrombopag for the Treatment of Immune Thrombocytopenia: The Aegean Region of Turkey Experience. Turkish Journal of Haematology, 2015, 32, 323-328.	0.2	7
50	Necrotizing Fasciitis in Paroxysmal Nocturnal Hemoglobinuria. Case Reports in Hematology, 2015, 2015, 1-5.	0.3	7
51	Immune Thrombocytopenic Purpura: New Biological Therapy of an Old Disease. Current Medicinal Chemistry, 2015, 22, 1956-1962.	1.2	7
52	Seasonal Association of Immune Thrombocytopenia in Adults. Balkan Medical Journal, 2015, 32, 347-351.	0.3	7
53	Which dosing scheme is suitable for the taxanes? anin vitro model. Archives of Pharmacal Research, 2002, 25, 550-555.	2.7	6
54	Outcomes with frontline nilotinib treatment in Turkish patients with newly diagnosed Philadelphia chromosome–positive chronic myeloid leukemia in chronic phase. Expert Opinion on Pharmacotherapy, 2016, 17, 1851-1858.	0.9	6

#	Article	IF	CITATIONS
55	Carfilzomib experience in relapsed/refractory multiplemyeloma: a single-center experience. Turkish Journal of Medical Sciences, 2018, 48, 80-83.	0.4	6
56	Gossypol exerts its cytotoxic effect on HL-60 leukemic cell line via decreasing activity of protein phosphatase 2A and interacting with human telomerase reverse transcriptase activity. Hematology, 2010, 15, 144-150.	0.7	5
57	Ocular Adnexal Lymphomas: Single-Center Experience. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, S158-S160.	0.2	5
58	Can an oral antidiabetic (rosiglitazone) be of benefit in leukemia treatment?. Saudi Pharmaceutical Journal, 2015, 23, 14-21.	1.2	5
59	Frontline nilotinib treatment in Turkish patients with Philadelphia chromosome–positive chronic Myeloid Leukemia in chronic phase: updated results with 2 years of follow-up. Hematology, 2018, 23, 771-777.	0.7	5
60	A histopathological scoring and grading system to predict outcome for patients with AA amyloidosis. International Urology and Nephrology, 2020, 52, 1297-1304.	0.6	5
61	The Effect of Cryotherapy on the Prevention of Oral Mucositis and on the Oral pH Value in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation. Seminars in Oncology Nursing, 2021, 37, 151146.	0.7	5
62	Long-Term Effect of Ruxolitinib (RUX) in Inadequately Controlled Polycythemia Vera (PV) without Splenomegaly: 5-Year Results from the Phase 3 Response-2 Study. Blood, 2020, 136, 40-41.	0.6	5
63	Retrospective Evaluation of Patients Treated with Dasatinib for Philadelphia Positive Leukemias: Turkish Experience of 16 Months. UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi, 2009, 19, 195-204.	0.1	5
64	Combination of dasatinib and okadaic acid induces apoptosis and cell cycle arrest by targeting protein phosphatase PP2A in chronic myeloid leukemia cells. Medical Oncology, 2022, 39, 46.	1.2	5
65	Elevation of serum eosinophil cationic protein, soluble tumor necrosis factor receptors and soluble intercellular adhesion molecule-1 levels in acute bronchial asthma. Journal of Investigational Allergology and Clinical Immunology, 2002, 12, 211-4.	0.6	5
66	Intracranial Venous Thrombosis Associated with Severe Antithrombinâ€III Deficiency in Pregnancy. Journal of Obstetrics and Gynaecology Research, 2001, 27, 81-84.	0.6	4
67	Possible hepatosplenic candidiasis treated with liposomal amphotericin B and caspofungin combination. Journal of Infection, 2006, 52, 387-388.	1.7	4
68	Amyloid deposition in knee and ankle joints in the course of multiple myeloma. Joint Bone Spine, 2007, 74, 209-211.	0.8	4
69	Metastatic Pulmonary Calcinosis and Leukocytoclastic Vasculitis in a Patient with Multiple Myeloma. Turkish Journal of Haematology, 2012, 29, 397-400.	0.2	4
70	Progressive Transformation of Germinal Centers: Single-Center Experience of 33 Turkish Patients. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, S149-S151.	0.2	4
71	The effect of polycythemia vera on hearing functions: Evaluation of twentyâ€one patients. Clinical Otolaryngology, 2019, 44, 434-437.	0.6	4
72	The role of PET/CT in evaluation of bone marrow involvement in lymphoma patients at the initial staging. Marmara Medical Journal, 2017, 30, 1-1.	0.2	4

#	Article	IF	CITATIONS
73	Patient characteristics and management practices in chronic myeloid leukemia in Turkey: reflections from an expert meeting. Expert Review of Hematology, 2022, 15, 97-106.	1.0	4
74	Potential involvement of serine/threonine protein phosphatases in apoptosis of HepG2 cells during selenite treatment. Biological Trace Element Research, 2007, 117, 65-75.	1.9	3
75	Primary cutaneous Bâ€cell lymphoma: report of eight cases and review of the literature. International Journal of Dermatology, 2008, 47, 675-680.	0.5	3
76	The interaction between taxoids and serine/threonine protein phosphatase activities during taxan-induced apoptosis of HL 60 leukemic cells. Hematology, 2008, 13, 215-223.	0.7	3
77	Two cases with hypereosinophilic syndrome shown with real-time PCR and responding well to imatinib treatment. Molecular Biology Reports, 2013, 40, 1591-1597.	1.0	3
78	Epidemiology and analysis of invasive fungal infections in patients withhematological malignancies: a single-center real-life experience. Turkish Journal of Medical Sciences, 2017, 47, 1535-1542.	0.4	3
79	Retrospective analysis of primary gastric diffuse largeB-cell lymphoma: a single center study from Turkey. Turkish Journal of Medical Sciences, 2017, 47, 240-245.	0.4	3
80	Efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/ refractory multiple myeloma: a real-life experience. Turkish Journal of Medical Sciences, 2018, 48, 777-785.	0.4	3
81	Ruxolitinib for the Treatment of Inadequately Controlled Polycythemia Vera without Splenomegaly: 156-Week Follow-up from the Phase 3 Response-2 Study. Blood, 2018, 132, 1754-1754.	0.6	3
82	RESPONSE 2: A phase 3b study evaluating the efficacy and safety of ruxolitinib in patients with hydroxyurea (HU)-resistant/intolerant polycythemia vera (PV) versus best available therapy (BAT) Journal of Clinical Oncology, 2014, 32, TPS7128-TPS7128.	0.8	3
83	Retrospective analysis of patients with relapsed or refractory testicular nonseminous germ cell tumors treated with autologous stem cell transplantation. Indian Journal of Cancer, 2017, 54, 415.	0.2	3
84	PNH is a debilitating, fatal but treatable disease: same disease, different clinical presentations. American Journal of Blood Research, 2015, 5, 30-3.	0.6	3
85	Acral Sclerosis due to Interferon-Alpha-2b in Chronic Myelogenous Leukemia. Acta Haematologica, 2002, 107, 43-45.	0.7	2
86	Factor V G1691A (Leiden) and prothrombin G20210A gene mutation status, and thrombosis in patients with chronic myeloproliferative disorders. Turkish Journal of Haematology, 2011, 2011, 306-311.	0.2	2
87	Toxic epidermal necrolysis associated with radiotherapy and phenytoin in a patient with non-Hodking's lymphoma: A case report. Reports of Practical Oncology and Radiotherapy, 2016, 21, 81-83.	0.3	2
88	Extramedullary Relapse in a CML Patient after Allogeneic Stem Cell Transplantation. Case Reports in Hematology, 2017, 2017, 1-3.	0.3	2
89	Determining expression of miRNAs that potentially regulateSTAT5A and 5B in dasatinib-sensitive K562 cells. Turkish Journal of Biology, 2017, 41, 926-934.	2.1	2
90	Effects of Rituximab on JAK-STAT and NF-κB signaling pathways in acute lymphoblastic leukemia and chronic lymphocytic leukemia. Turkish Journal of Biochemistry, 2019, 44, 499-509.	0.3	2

#	Article	IF	CITATIONS
91	Efficacy and Safety of Ibrutinib Therapy in Patients with Chronic Lymphocytic Leukemia: Retrospective Analysis of Real-Life Data. Turkish Journal of Haematology, 2021, 38, 273-285.	0.2	2
92	TET2, ASXL1, IDH1, and IDH2 Single Nucleotide Polymorphisms in Turkish Patients with Chronic Myeloproliferative Neoplasms. Turkish Journal of Haematology, 2017, 34, 174-178.	0.2	2
93	Vena cava superior syndrome due to sternal plasmacytoma in the course of systemic myeloma. Haematologia, 2002, 32, 529-33.	0.2	2
94	Red grape seed extract and its compound resveratrol exert cytotoxic effect to various human cancer lines. Turkish Journal of Haematology, 2007, 24, 102-9.	0.2	2
95	A case of acute lymphoblastic leukemia with additional chromosomes X and 5 associated with a Philadelphia chromosome in the bone marrow. Turkish Journal of Haematology, 2010, 27, 299-302.	0.2	1
96	MOLECULAR EVALUATION OF t(14;18)(bcl-2/lgH) TRANSLOCATION IN FOLLICULAR LYMPHOMA AT DIAGNOSIS USING PARAFFIN-EMBEDDED TISSUE SECTIONS. Turkish Journal of Haematology, 2012, 29, 126-134.	0.2	1
97	Risk factors for poor mobilization in solid tumors: How effectively can we mobilize patients with solid tumors?. Transfusion and Apheresis Science, 2017, 56, 809-813.	0.5	1
98	Efficacy and Safety of Ruxolitinib in 132 Turkish Patients with Myelofibrosis: A Multicenter and Retrospective Analysis. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, S265.	0.2	1
99	Retrospective Analysis of Hairy Cell Leukemia Patients Treated with Different Modalities as First Line: Real-Life Experience Over 20Âyears. Indian Journal of Hematology and Blood Transfusion, 2019, 35, 692-698.	0.3	1
100	Epigenetic modifications in chronic myeloid leukemia cells through ruxolitinib treatment. Journal of Cellular Biochemistry, 2019, 120, 4555-4563.	1.2	1
101	Radioisotope Synovectomy for Treating Chronic Synovitis in Inhibitor Patients with Hemophilia Blood, 2006, 108, 4005-4005.	0.6	1
102	Investigating the cytotoxic and apoptotic effects of sunitinib upon K-562 chronic myelogenous leukemia cell line and assessment of gene profiling. Journal of Cancer Research and Therapeutics, 2020, 16, 150.	0.3	1
103	Alterations in the activity and expression of serine/threonine protein phosphatases during all trans retinoic acid-induced apoptosis in breast cancer cells. Oncology Reports, 0, , .	1.2	1
104	The Clinical Characteristics and Therapeutic Outcomes of Elderly Patients with Chronic Lymphocytic Leukemia: A Retrospective Multicenter Study. Blood, 2014, 124, 5644-5644.	0.6	1
105	Report On Three Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm. Turkish Journal of Haematology, 2018, 35, 211-212.	0.2	1
106	Role of Allogeneic Stem Cell Transplant in the Treatment of Primary Myelofibrosis. Experimental and Clinical Transplantation, 2019, 17, 93-96.	0.2	1
107	Patterns of Hydroxyurea Prescription and Use in Routine Clinical Management of Polycythaemia Vera: a Multicentre Chart Review Study. Turkish Journal of Haematology, 2020, 37, 177-185.	0.2	1
108	Comparative expression analysis of dasatinib and ponatinib-regulated IncRNAs in chronic myeloid leukemia and their network analysis. Medical Oncology, 2022, 39, 29.	1.2	1

#	Article	IF	CITATIONS
109	Potential Involvement of Calcineurin in Regulating the State of Differentiation and Apoptosis of HL-60 Cells During Methylprednisolone-Treatment. Turkish Journal of Haematology, 2003, 20, 143-51.	0.2	1
110	Non-Hodgkin's Lymphoma of the Breast: Report of Five Cases and Review of the Literature. UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi, 2012, 22, 195-201.	0.1	0
111	miR17 Suppresses Cell Proliferation in Zoledronic Acid Treated Chronic Myeloid Leukemia Cells by Inducing Autophagy. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, S213.	0.2	0
112	Evaluation of Febrile Neutropenic Episodes in Autologous Hematopoietic Stem Cell Transplantations for Hodgkin Lymphoma. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, S40-S41.	0.2	0
113	Investigating The Role of JAK/STAT Pathway upon Dasatinib Induced Apoptosis for CML Cell Model K562. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, S209-S210.	0.2	0
114	Resveratrol Increases CHD4 Gene Expression and Regulates Wnt Signaling in Chronic Myeloid Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, S215.	0.2	0
115	Ocular Adnexal Lymphomas: Experience of Single Center. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, S217.	0.2	0
116	Evaluation of Febrile Neutropenic Episodes in Autologous Hematopoietic Stem Cell Transplantations for NHL. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, S71-S72.	0.2	0
117	The Effect of Polycythemia Vera on Hearing Functions. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, S94-S95.	0.2	0
118	Response: upfront nilotinib therapy among patients with chronic myeloid leukemia in chronic phase. Expert Opinion on Pharmacotherapy, 2017, 18, 327-328.	0.9	0
119	Adult Onset Langerhans Cell Histiocytosis: A Single Center Experience. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, S269.	0.2	0
120	Castleman's Disease: The Experience Over 17 Years. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, S270.	0.2	0
121	Successful Treatment of Patients with AML and MDS by Decitabine: Single Centre Experience. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, S260-S261.	0.2	0
122	Clinical Features and Outcomes of Solitary Plasmacytomas: Single-CenterÂExperience from Turkey. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, S235.	0.2	0
123	Efficacy and safety of ruxolitinib in patients with myelofibrosis: a retrospective and multicenter experience in Turkey. Turkish Journal of Medical Sciences, 2021, 51, 1033-1042.	0.4	0
124	Hematopoietic Stem Cell Transplantation for Patients with Paroxysmal Nocturnal Hemoglobinuria with or Without Aplastic Anemia: Multicenter Turkish Experience. Turkish Journal of Haematology, 2021, 38, 195-203.	0.2	0
125	Experimental Repair of Rabbit Segmental Bone Defects by Using Autologous Bone Marrow and Electrical Stimulation. Turkiye Klinikleri Journal of Medical Sciences, 2010, 30, 623-630.	0.1	0
126	The Potential Role of STAT's in Anti-Leukemic Therapy with Different Drugs. Blood, 2012, 120, 5120-5120.	0.6	0

#	Article	IF	CITATIONS
127	Autophagic and Apoptotic Effects of Tyrosine Kinase Inhibitors in Myeloid Leukemia: Comparison of Three Generation. Blood, 2012, 120, 4915-4915.	0.6	ο
128	Polyethylene Glycol - Polyethylenimine Nanoparticle-Mediated Transfection of Mir-150 Into the Leukemia Cells and Determination of the Expression Pattern Changes in Apoptosis and Cell Cycle Genes. Blood, 2012, 120, 4679-4679.	0.6	0
129	Use Of Nilotinib As a First Line Treatment In Adult Patients With Philadelphia Chromosome-Positive and Chronic Phase Myeloid Leukemia. Blood, 2013, 122, 2742-2742.	0.6	0
130	Nilotinib Results in Improved Rates of Molecular Response in Turkish Newly Diagnosed CML-CP Patients: A 24-Month Update. Blood, 2014, 124, 5532-5532.	0.6	0
131	Molecular Subtype Distribution and Cyclooxygenase-2 Expression Situation in Inflammatory Breast Cancer. Meandros Medical and Dental Journal, 2016, 17, 54-58.	0.1	Ο
132	Role of consolidative radiation therapy for patients with mediastinal diffuse large B-cell lymphoma in the rituximab era. Journal of Cancer Research and Therapeutics, 2018, 14, 1397-1402.	0.3	0
133	Hemophilia Patients' Level of Knowledge of About Viral Hepatitis. Mediterranean Journal of Infection, Microbes and Antimicrobials, 0, , .	0.2	0
134	Acquired haemophilia A in an elderly patient related to relapsed cervix carcinoma. The Journal of Haemophilia Practice, 2018, 5, 143-146.	0.2	0
135	Is Allogeneic Stem Cell Transplantation a Good Option for Paroxysmal Nocturnal Haemoglobinuria?. European Medical Journal Hematology, 0, , .	0.0	Ο
136	Evaluation of clinical characteristics of patients with paroxysmal nocturnal hemoglobinuria treated with eculizumab in Turkey: a multicenter retrospective analysis. American Journal of Blood Research, 2021, 11, 279-285.	0.6	0
137	An Interim Analysis of the Turkish Myeloma Registry Among the Patients Who Have Received up to Two Lines of Therapy. Blood, 2021, 138, 4730-4730.	0.6	Ο
138	<i>Origanum Sipyleum</i> Methanol Extract in Combination with Ponatinib Shows Synergistic anti-Leukemic Activities on Chronic Myeloid Leukemia Cells. Nutrition and Cancer, 2022, 74, 3679-3691.	0.9	0
139	Turkey real-life data: demographic features, treatment results and effects of comorbidities in chronic myeloid leukemia. International Journal of Hematologic Oncology, 0, , .	0.7	0